

Supplementary Table 1: Patient and disease characteristics

(A) All patients

	All patients (n=42)
Age, yrs, median (IQR)	67 (64–70)
PSA, ng/ml, median (IQR)	10.2 (5.7–22.5)
Pathologic classification, n	
T2a	1
T2b	0
T2c	18
T3a	12
T3b	11
T4	0
Pathologic Gleason score, n	
3+3	5
3+4	10
4+3	14
4+4	2
3+5	1
5+3	1
4+5	7
5+4	2
Number lymph nodes removed, median (IQR)	35 (26–42)

(B) Patients who received sextant ICG injections

	All patients (n=12)
Age, yrs, median (IQR)	67.5 (60.8–71.5)
PSA, ng/ml, median (IQR)	11.2 (5.2–46.7)
Pathologic classification, n	
T2a	0
T2b	0
T2c	4 (33)
T3a	5 (42)
T3b	3 (25)
T4	0
Pathologic Gleason score, n	
3+3	2 (17)
3+4	2 (17)
4+3	4 (33)
4+4	0
3+5	0
5+3	0
4+5	4 (33)
5+4	0
Number lymph nodes removed, median (IQR)	31 (24–42)

Abbreviations: IQR, interquartile range; PSA, prostate-specific antigen.